432
Participants
Start Date
June 6, 2023
Primary Completion Date
July 15, 2026
Study Completion Date
August 1, 2030
Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]
The beta-agonist oral medication will be prescribed and dose adjusted per usual care.
OnabotulinumtoxinA 100 UNT [Botox]
OnabotulinumtoxinA will be prepared by dissolving 100 units into 10 ml of injectable saline. The injection will be an office based procedure, performed per usual care.
RECRUITING
Howard University, Washington D.C.
RECRUITING
University of Alabama at Birmingham, Birmingham
RECRUITING
University of New Mexico, Albuquerque
RECRUITING
University of California, San Diego, San Diego
RECRUITING
Women & Infants Hospital of Rhode Island, Providence
Collaborators (1)
University of New Mexico
OTHER
University of Alabama at Birmingham
OTHER
University of California, San Diego
OTHER
Howard University
OTHER
Brown University
OTHER
Patient-Centered Outcomes Research Institute
OTHER
Women and Infants Hospital of Rhode Island
OTHER